Bio-Techne Corporation Stock

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:47:14 2024-06-17 EDT 5-day change 1st Jan Change
75.59 USD -0.37% Intraday chart for Bio-Techne Corporation -1.50% -1.58%
Sales 2024 * 1.16B 1.59B Sales 2025 * 1.25B 1.72B Capitalization 11.96B 16.44B
Net income 2024 * 180M 247M Net income 2025 * 228M 313M EV / Sales 2024 * 10.5 x
Net Debt 2024 * 166M 228M Net cash position 2025 * 85.4M 117M EV / Sales 2025 * 9.51 x
P/E ratio 2024 *
67.8 x
P/E ratio 2025 *
54.2 x
Employees 3,050
Yield 2024 *
0.42%
Yield 2025 *
0.42%
Free-Float 99.03%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
Transcript : Bio-Techne Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:30 AM
Transcript : Bio-Techne Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 09:20 AM
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference CI
Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration CI
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing MT
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80 MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept MT
Baird Adjusts Bio-Techne Price Target to $81 From $73 MT
More news
1 day-0.33%
1 week-1.50%
Current month-1.62%
1 month-9.38%
3 months+5.65%
6 months-0.11%
Current year-1.58%
More quotes
1 week
74.79
Extreme 74.79
78.99
1 month
74.79
Extreme 74.79
84.22
Current year
61.16
Extreme 61.16
85.57
1 year
51.79
Extreme 51.79
89.91
3 years
51.79
Extreme 51.79
135.96
5 years
38.79
Extreme 38.7925
135.96
10 years
19.99
Extreme 19.9875
135.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 18-04-29
Director of Finance/CFO 53 14-03-31
Chief Operating Officer 55 01-07
Members of the board TitleAgeSince
Chairman 68 02-12-31
Director/Board Member 74 89-12-31
Director/Board Member 71 17-10-25
More insiders
Date Price Change Volume
24-06-17 75.24 -0.83% 36 132
24-06-14 75.87 -1.31% 787,761
24-06-13 76.88 -0.74% 529,506
24-06-12 77.45 +0.73% 782,456
24-06-11 76.89 -0.27% 827,522

Delayed Quote Nasdaq, June 17, 2024 at 09:31 am

More quotes
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
75.87 USD
Average target price
84.02 USD
Spread / Average Target
+10.74%
Consensus